Abbott landed CE Mark approval in the European Union to introduce its Absorb GT1 bioresorbable vascular scaffold system. The dissolvable stent is delivered via the matching GlideTrack catheter, Abbott’s flagship delivery catheter designed for optimal access through difficult anatomy, allowing its use in wide range of patients.

GT1-device-partsThe stent itself has already been used in over 100,000 patients around the world, but the new delivery catheter has been freshly designed to improve the placement of the stent.

From Abbott’s announcement:

Last year, Abbott announced positive one-year clinical results from ABSORB II, the world’s first prospective, randomized, controlled trial comparing the safety and effectiveness of the fully dissolving Absorb heart device to Abbott’s market-leading, metallic XIENCE family of drug eluting stents. At one year, overall clinical outcomes for Absorb were comparable to XIENCE. The trial, conducted primarily in Europe, included 501 people with CAD. At EuroPCR, a scientific meeting for cardiologists held in Paris, Absorb data will be presented throughout the conference, which runs from May 19-21, 2015.  EuroPCR is the official congress of the European Association of Percutaneous Cardiovascular Interventions, with the goal of reducing the burden of cardiovascular disease.